445680 - Curiox Biosystems Co., Ltd.

445680 Summary

Medical Devices

Stock Price & Overview

₩47,650 -750 (-1.55%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩47,650 ≈ US$34 · Market cap ₩0.8tn (≈ $586m)

445680 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021
Total Revenue	5.2	4.6	6.8	7.2	5.5
Cost of Revenue	3.0	2.0	3.0	2.5	2.0
Gross Profit	2.1	2.6	3.8	4.7	3.5
Selling, General & Administrative	14.4	15.9	14.4	16.2	11.8
Operating Income	-12.3	-13.4	-10.6	-11.4	-8.3
Finance Income	18.3	9.2	1.3	3.0	0.4
Finance Costs	32.7	3.7	0.9	3.0	7.0
Pretax Income	-27.3	-8.0	-10.2	-11.3	-14.7
Income Tax Expense	-0.2	0.1	-0.2	0.2	-0.2
Net Income	-27.2	-8.1	-10.0	-11.5	-14.5
Total Comprehensive Income	-25.8	-5.3	-8.9	-8.9	-12.3

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	78.0	70.6	57.8	48.6	55.8
Current Assets	40.2	32.3	21.6	13.9	23.1
Cash & Cash Equivalents	14.8	24.2	17.9	5.6	11.0
Inventories	1.7	1.8	1.6	2.9	1.8
Trade Receivables	1.8	0.6	1.7	1.8	1.2
Non-current Assets	37.9	38.3	36.2	34.7	32.7
Property, Plant & Equipment	1.2	1.4	1.4	0.6	0.2
Intangible Assets	35.9	36.0	33.6	33.5	32.1
Total Liabilities	25.2	21.9	4.9	4.8	50.2
Current Liabilities	23.4	19.9	2.7	2.8	48.4
Non-current Liabilities	1.8	2.0	2.2	1.9	1.8
Total Equity	52.8	48.6	52.9	43.9	5.6
Share Capital	8.6	8.1	4.0	3.3	0.5
Retained Earnings	-80.7	-53.6	-45.5	-35.4	-23.9

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021
Cash from Operating Activities	-11.1	-9.7	-8.2	-9.9	-5.1
Cash from Investing Activities	0.9	-4.3	2.9	4.7	-8.3
Purchase of Property, Plant & Equipment	0.1	0.3	0.2	0.8	0.3
Cash from Financing Activities	0.4	19.9	17.6	-0.2	17.0
Net Change in Cash	-9.8	5.9	12.4	-5.4	3.6

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	1.2	1.3	1.8	1.4	1.0	0.9	1.0	1.0	1.1	1.6
Cost of Revenue	0.7	0.8	0.9	0.6	1.3	0.3	0.3	0.4	0.5	0.7
Gross Profit	0.4	0.6	1.0	0.8	-0.3	0.6	0.6	0.5	0.6	0.8
Selling, General & Administrative	4.9	3.8	3.6	3.5	3.7	3.6	4.2	3.8	3.8	4.1
Operating Income	-4.5	-3.3	-2.7	-2.7	-4.0	-3.0	-3.6	-3.3	-3.2	-3.3
Finance Income	13.3	0.9	14.5	0.4	2.7	0.6	7.9	0.1	0.7	0.6
Finance Costs	13.7	0.2	14.1	0.8	16.7	1.1	2.5	0.8	0.3	0.1
Pretax Income	-4.9	-2.6	-2.3	-3.0	-18.4	-3.7	1.7	-4.1	-2.8	-2.8
Income Tax Expense	-0.0	0.0	-0.0	-0.0	-0.1	-0.0	0.0	-0.0	0.2	-0.1
Net Income	-4.8	-2.6	-2.3	-3.0	-18.3	-3.6	1.7	-4.0	-3.1	-2.7
Total Comprehensive Income	-4.3	-1.3	-1.4	-2.5	-18.7	-3.2	2.7	-3.5	-2.3	-2.1

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	53.3	77.7	78.0	64.6	65.4	67.9	70.6	72.2	53.0	55.5
Current Assets	13.8	38.4	40.2	27.6	29.0	29.7	32.3	35.3	16.0	18.9
Cash & Cash Equivalents	10.5	10.1	14.8	17.7	20.2	11.3	24.2	30.1	13.1	10.4
Inventories	1.5	1.7	1.7	1.3	1.2	2.1	1.8	1.7	1.6	1.6
Trade Receivables	0.7	1.2	1.8	1.2	1.0	0.6	0.6	0.7	0.8	1.4
Non-current Assets	39.5	39.3	37.9	37.0	36.4	38.1	38.3	36.9	37.0	36.6
Property, Plant & Equipment	1.1	1.1	1.2	1.2	0.9	1.2	1.4	1.4	1.4	1.4
Intangible Assets	37.7	37.4	35.9	35.3	34.8	36.1	36.0	34.6	34.6	34.0
Total Liabilities	4.3	26.0	25.2	10.9	38.2	22.3	21.9	26.6	4.2	4.7
Current Liabilities	2.6	24.2	23.4	9.2	36.4	20.4	19.9	24.6	2.1	2.7
Non-current Liabilities	1.7	1.8	1.8	1.7	1.7	1.9	2.0	2.0	2.1	2.0
Total Equity	49.0	51.7	52.8	53.8	27.2	45.6	48.6	45.7	48.8	50.8
Share Capital	8.6	8.6	8.6	8.5	8.1	8.1	8.1	8.0	4.0	4.0
Retained Earnings	-88.2	-83.4	-80.7	-78.5	-75.4	-57.2	-53.6	-55.2	-51.2	-48.1

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	-2.8	-1.1	-3.1	-2.3	-2.6	-3.2	-2.1	-2.9	-2.3	-2.4
Cash from Investing Activities	6.6	-3.6	-0.0	-1.0	12.0	-10.0	-4.2	-0.0	4.9	-5.0
Purchase of Property, Plant & Equipment	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.0
Cash from Financing Activities	-3.3	-0.1	0.0	0.5	-0.0	-0.0	0.0	20.0	-0.0	-0.1
Net Change in Cash	0.4	-4.8	-3.1	-2.8	9.4	-13.3	-6.2	17.1	2.6	-7.5

Consolidated (CFS), from DART. 5 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

445680 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	5.2	+12.3%	-10.7%	—	—
Operating income	-12.3	—	—	—	—
Net income	-27.2	—	—	—	—
EPS	₩-1,579	—	—	—	—
Operating cash flow	-11.1	—	—	—	—
Shareholders' equity	52.8	+8.6%	+6.4%	—	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

445680 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021
Gross margin	41.5%	55.8%	56.4%	65.4%	63.3%
Operating margin	-239.0%	-291.6%	-155.5%	-157.8%	-151.0%
Net margin	-527.6%	-176.3%	-147.9%	-158.9%	-263.0%
Return on equity	-53.6%	-15.9%	-20.8%	-46.5%	-259.7%
Return on assets	-36.6%	-12.6%	-18.9%	-22.0%	-26.0%
Operating cash flow / revenue	-215.6%	-211.4%	-120.3%	-136.6%	-92.8%
Capex / revenue	2.6%	5.6%	3.1%	11.4%	4.7%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 445680

Symbol	Last Price
096530Seegene, Inc.	₩31,900 +1.1%
491000Livs Med, Inc.	₩34,500 +3.6%
041830In Body Co., Ltd.	₩61,100 +2.5%
458870Seers Co., Ltd.	₩21,350 +3.1%
137310SD Biosensor	₩6,160 -0.3%
377740Bio Note, Inc.	₩4,790 -0.2%
340570T & L Co., Ltd.	₩29,650 +1.2%
099190i-SENS, Inc.	₩16,470 +0.0%
336570WON Tech Co., Ltd.	₩4,905 +0.9%
174900Ab Clon, Inc.	₩21,600 +5.9%

Compare all 13 in Medical Devices

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.